Halozyme Therapeutics, Inc. and Genentech, a member of the Roche Group, have entered an agreement to collaborate on clinical studies evaluating as many as eight different tumor types beginning in 2017. The first Phase Ib/II study, led by Genentech, will evaluate their cancer immunotherapy Tecentriq (atezolizumab), an anti-PD-L1 monoclonal antibody, in combination with Halozyme’s investigational drug, PEGPH20 in six tumor types. Halozyme will supply the drug for the Genentech study. This...